Palisade's PALI-2108 Shows Tolerability Across 15mg To 450mg Doses In Ulcerative Colitis Study

(RTTNews) - Palisade Bio, Inc. (PALI), Thursday announced a preliminary data from five planned Single Ascending Dose cohorts, showing that PALI-2018 was well-tolerated among doses ranging from 15 mg to 450 mg.

The data comes from an ongoing Phase 1a/b study for the treatment of Ulcerative Colitis, which also noted absence of treatment-related dose reductions, serious adverse events, or treatment-related laboratory abnormalities.

Additionally, preliminary pharmacokinetic analysis from the SAD portion of the study demonstrated the delayed-release and extended-release characteristics of PALI-2108.

The biotechnology company also announced the commencement of the Multiple Ascending Dose cohorts, aiming to assess repeat dosing and the evaluation of the safety and pharmacokinetics of PALI-2108 in both healthy volunteers and UC patients.

In the pre-market hours, Palisade's stock is climbing 10.23 percent, to $1.94 on the Nasdaq.